tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ami Fadia, 395 are a BUY (87.58%), 52 are a HOLD (11.53%), 4 are a SELL (0.89%).
Analyst Ami Fadia, currently employed at NEEDHAM, carries an average stock price target met ratio of 37.16% that have a potential upside of 32.08% achieved within 160 days.
Ami Fadia’s has documented 869 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IMRX, Immuneering Corp at 29-Sep-2025.
Analyst best performing recommendations are on IMRX (IMMUNEERING CORP).
The best stock recommendation documented was for RVMD (REVOLUTION MEDICINES) at 10/12/2023. The price target of $34 was fulfilled within 4 days with a profit of $9.8 (40.5%) receiving and performance score of 101.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell
$12
$-6.23 (-34.17%)
$7
3 months 23 days ago
(25-Jun-2025)
8/13 (61.54%)
$-4.19 (-25.88%)
55
Buy
1 years 4 months ago
(18-Jun-2024)
10/37 (27.03%)
$101 (102.02%)
298
Sell
1 years 10 months 28 days ago
(19-Nov-2023)
1/3 (33.33%)
$-0.8 (-0.99%)
300
Hold
$20
$1.77 (9.71%)
$60
1 years 11 months 23 days ago
(25-Oct-2023)
3/22 (13.64%)
$5.72 (40.06%)
40
Hold
$25
$6.77 (37.14%)
$40
2 years 2 months 29 days ago
(19-Jul-2023)
2/5 (40%)
$3.4 (15.74%)
215
Which stock is Ami Fadia is most bullish on?
Which stock is Ami Fadia is most reserved on?
What Year was the first public recommendation made by Ami Fadia?
